Czech
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
antirheumatics/nauzea
Odkaz je uložen do schránky
Strana 1 z 75 Výsledek
Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy.
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
OBJECTIVE
To evaluate tolerability and efficacy of combination therapy with methotrexate (MTX)/parenteral gold or MTX/other disease modifying antirheumatic drug (DMARD, d-penicillamine or chloroquine) in comparison with MTX monotherapy in patients with longstanding destructive active rheumatoid
Granisetron (Kytril) suppresses methotrexate-induced nausea and vomiting among patients with inflammatory arthritis and is superior to prochlorperazine (Stemetil).
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
OBJECTIVE
Methotrexate (MTX) is an increasingly popular anti-rheumatic drug with its usefulness limited by toxicity, most commonly gastrointestinal (GI). The aim of the study was to study the effectiveness of the 5-HT3 receptor antagonist granisetron (GR) in the therapy of MTX-induced
Efficacy of roxithromycin in adult patients with rheumatoid arthritis who had not received disease-modifying antirheumatic drugs: a 3-month, randomized, double-blind, placebo-controlled trial.
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
BACKGROUND
It has been reported that antibodies to oral anaerobic bacteria are elevated in the serum and synovial fluids of patients with rheumatoid arthritis. Macrolide antibiotics are active against oral anaerobic bacteria.
OBJECTIVE
The aim of this work was to evaluate the clinical efficacy of
Drug-Induced Gastrointestinal and Hepatic Disease Associated with Biologics and Nonbiologic Disease-Modifying Antirheumatic Drugs.
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
A variety of gastrointestinal adverse drug reactions are seen in nearly all conventional antirheumatic medications, ranging from nausea to life-threatening drug-induced liver injury. Rheumatologists should be particularly familiar with hepatotoxicity associated with long-term methotrexate use, and
Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis.
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
To evaluate the efficacy and safety of orally administered once-daily peficitinib in combination with limited conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) in patients with moderate-to-severe rheumatoid arthritis (RA).
In this randomized, double-blind, phase IIb trial,
Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial.
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
Upadacitinib is a selective inhibitor of Janus kinase 1 and was efficacious in phase 2 studies in patients with moderate-to-severe rheumatoid arthritis. We aimed to assess the efficacy of upadacitinib in patients with inadequate response to conventional synthetic disease-modifying anti-rheumatic
Methotrexate-induced nausea in the treatment of juvenile idiopathic arthritis.
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
BACKGROUND
Methotrexate is the most commonly used disease modifying antirheumatic drug in the treatment of juvenile idiopathic arthritis and can be effective in controlling disease in many patients.
UNASSIGNED
A significant proportion of patients experience nausea and vomiting induced by
Toxicity profiles of traditional disease modifying antirheumatic drugs for rheumatoid arthritis.
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
BACKGROUND
The progression of rheumatoid arthritis (RA) can be retarded or halted by disease modifying antirheumatic drugs (DMARDs). Next to inefficacy, toxicity limits their use.
OBJECTIVE
To explore the toxicity profiles of DMARDs in daily life.
METHODS
Five hundred and ninety three patients with
[Gastrointestinal complications in treatment with classical nonsteroidal antirheumatic agents].
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
The most frequent gastro-intestinal complications in classical NSAID treatment are presented. Nausea and dispepsy are present in 60 percent, and gastric erosions in 50 percent of patients on regular NSAID treatment. COX-2 inhibitors with lower rate of gastro-intestinal complications are mentioned.
Long-term treatment of destructive rheumatoid arthritis with methotrexate.
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
OBJECTIVE
To evaluate the tolerability and efficacy of methotrexate (MTX) treatment in patients with longstanding, progressive, active rheumatoid arthritis (RA) who had failed one or more disease modifying antirheumatic drugs (DMARD).
METHODS
Two hundred seventy-one consecutive patients with RA in
Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group.
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
BACKGROUND
Phase II trials of leflunomide, an inhibitor of de-novo pyrimidine synthesis, have shown efficacy in rheumatoid arthritis. This double-blind randomised trial compared leflunomide with placebo and sulphasalazine in active rheumatoid arthritis.
METHODS
358 patients were randomly assigned
Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine.
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
OBJECTIVE
Recent studies have demonstrated the short term efficacy of leflunomide. This study evaluates the efficacy and safety of leflunomide and sulfasalazine in rheumatoid arthritis over a two year follow up period.
METHODS
358 patients with rheumatoid arthritis in a double blind trial were
Frequency of methotrexate intolerance in rheumatoid arthritis patients using methotrexate intolerance severity score (MISS questionnaire).
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
The objective of the study was to determine the frequency of methotrexate intolerance in rheumatoid arthritis (RA) patients by applying the methotrexate intolerance severity score (MISS) questionnaire and to see the effect of dose and concomitant use of other disease-modifying antirheumatic drugs
The efficacy and safety of antidepressants in inflammatory arthritis: a Cochrane systematic review.
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
OBJECTIVE
To determine the efficacy and safety of antidepressants in pain management in patients with inflammatory arthritis (IA).
METHODS
We searched the Cochrane Central Register of Controlled Trials, Medline, Embase, and PsychINFO for randomized controlled trials in adults with IA that compared
[Treatment with low-dose methotrexate in chronic polyarthritis. Review of the literature].
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
The therapeutic effect of low-dose MTX-treatment (10-25 mg/week) in active rheumatoid arthritis can be demonstrated by an improvement in clinical and laboratory parameters of disease activity already after 4-6 weeks. The mode of action is not fully understood. Direct anti-inflammatory effects seem
Nejúplnější databáze léčivých bylin podložená vědou
- Funguje v 55 jazycích
- Bylinné léky podporované vědou
- Rozpoznávání bylin podle obrázku
- Interaktivní mapa GPS - označte byliny na místě (již brzy)
- Přečtěte si vědecké publikace související s vaším hledáním
- Hledejte léčivé byliny podle jejich účinků
- Uspořádejte své zájmy a držte krok s novinkami, klinickými testy a patenty
Zadejte symptom nebo chorobu a přečtěte si o bylinách, které by vám mohly pomoci, napište bylinu a podívejte se na nemoci a příznaky, proti kterým se používá.
* Všechny informace vycházejí z publikovaného vědeckého výzkumu
